Provided by Tiger Trade Technology Pte. Ltd.

Hoth Therapeutics

0.8056
-0.0333-3.97%
Post-market: 0.82140.0158+1.96%19:39 EDT
Volume:161.70K
Turnover:130.96K
Market Cap:12.50M
PE:-0.79
High:0.8326
Open:0.8303
Low:0.7900
Close:0.8389
52wk High:2.12
52wk Low:0.6554
Shares:15.51M
Float Shares:14.96M
Volume Ratio:0.59
T/O Rate:1.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0134
EPS(LYR):-1.2844
ROE:-151.13%
ROA:-84.46%
PB:1.52
PE(LYR):-0.63

Loading ...

Hoth Therapeutics Inc - Over 65% of Patients Reported Reductions in Pain and Itching

THOMSON REUTERS
·
Feb 25

Hoth Therapeutics Accelerates Ht-001 Trial Enrollment With New Clinical Site as Patient Demand Increases

THOMSON REUTERS
·
Feb 25

Hoth Therapeutics Inc - Zero Patients Required Dose Reduction or Discontinuation

THOMSON REUTERS
·
Feb 25

Hoth Therapeutics Inc - 100% of Cohort Patients Achieved Primary Efficacy Endpoint in Interim Cleer-001 Data

THOMSON REUTERS
·
Feb 25

Hoth Therapeutics Receives USPTO Notice of Allowance for Novel Exon-Skipping Therapy Patent Targeting Allergic Diseases

Reuters
·
Feb 12

BUZZ-Hoth Therapeutics rises as early obesity‑drug data in mice shows promise

Reuters
·
Feb 10

BRIEF-Hoth Therapeutics Announces Groundbreaking Positive Results Hoth's Ht-Va Gdnf Surpasses Semaglutide In Weight Loss

Reuters
·
Feb 10

Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's Ht-Va Gdnf Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model

THOMSON REUTERS
·
Feb 10

Hoth Therapeutics Inc - Gdnf Attenuates Weight Gain by 10-15% Leading to a Plateau in the Final Weeks of Treatment

THOMSON REUTERS
·
Feb 10

Hoth Therapeutics Inc - Gdnf Reduces Liver Weight by 20-30%

THOMSON REUTERS
·
Feb 10

EXCLUSIVE: Small Biotech Hoth Therapeutics Claims Experimental Obesity Drug Topped Famed Wegovy In Preclinical Study

Benzinga
·
Feb 10

Hoth Therapeutics Confirms It Holds No Cryptocurrency Assets

Reuters
·
Feb 05

Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets

THOMSON REUTERS
·
Feb 05

BRIEF-Hoth Therapeutics Delivers 100% Clinical Response With ~50% Reduction In Disease Severity In Open-Label PK Cohort Of EGFR-Treated Cancer Patients

Reuters
·
Jan 22

Hoth Therapeutics Inc - Additional Endpoints Show ~34% Improvement in Oncology Toxicity

THOMSON REUTERS
·
Jan 22

Hoth Therapeutics Inc - Ht-001 Well Tolerated With No Unexpected Safety Signals

THOMSON REUTERS
·
Jan 22

Hoth Therapeutics Delivers 100% Clinical Response With ~50% Reduction in Disease Severity in Open-Label Pk Cohort of Egfr-Treated Cancer Patients

THOMSON REUTERS
·
Jan 22

Hoth Therapeutics Secures Chinese Patent for HT-KIT Cancer Program, Strengthening Global Oncology IP Portfolio

Reuters
·
Jan 21

BRIEF-Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing Ht-001 Oncology Trial Toward Multi-Country Site Activation

Reuters
·
Jan 15

Hoth Therapeutics : Country-Specific Part Ii Regulatory Decisions in Hungary, Spain, & Poland Are Expected by Jan 19, 2026

THOMSON REUTERS
·
Jan 15